Cambridge Healthtech Institute’s 4th Annual

Gene Therapy Manufacturing
( 基因療法藥物的製造 )

Production Strategies for Vector-Based Gene Therapies

2019年8月15-16日


It is an exciting time for gene therapy – therapies on the market, strong investment and encouraging clinical data – but manufacturing still represents one of the major stumbling blocks to successful commercialization.

Cambridge Healthtech Institute’s Gene Therapy Manufacturing conference takes a practical, case-study driven approach to the process development, scale-up and production of gene therapies, tackling key topics such as AAV, lentivirus and retrovirus process development and scale-up, CMO management from early to late-stage development.

Preliminary Agenda

PROCESS DEVELOPMENT STRATEGIES FOR AAV GENE THERAPIES

KEYNOTE PRESENTATION: Present and Future of AAV Gene Therapy Technical Development and Manufacturing

Luis Maranga, PhD, Chief Technical Operations Officer, Voyager Therapeutics, Inc.

FEATURED PRESENTATION: Development, Optimization and Technology Transfer of the Scalable Pro10TM rAAV Manufacturing Process

Josh Grieger, PhD, CTO, Asklepios BioPharmaceutical

rAAV Vector Design, Capsid Directed Evolution and Scale Up Activities Using the BEVS System

Jacek Lubelski, PhD, Vice President, Global Pharmaceutical Development, uniQure

AAV Process Development

Justin Horvath, PhD, Director, Manufacturing, Regenxbio

AAV Vectors: From Discovery to Large-Scale Clinical Manufacturing: An Academic Success Story

Nathalie Clément, PhD, Associate Director and Associate Professor, Powell Gene Therapy Center, Pediatrics, University of Florida

Optimization of Transfection and Culture Conditions to Maximize AAV Production in Suspension 293-Based Cells

Bryan Piras, PhD, Senior Scientist II, Process Development, Therapeutics Production and Quality, St. Jude Children’s Research Hospital

Development of an Advance AAV Purification Platform Using Integrated Analytics and PAT

Florian Leseigneur, PhD, Viral Vector Development Team, Cell and Gene Therapy Catapult

AAV Purification or Viral Clearance

Jason Morais, PhD, DSP Lead, Gene Therapy Development, Sanofi

Development of High-Throughput Purification Methods for AAV

Matthew Kevin Roach, PhD, Senior Associate Scientist, Gene Therapy Process Development, Pfizer

Scalable Suspension Process Development for Viral Vectors

Sven Ansorge, PhD, Research Officer, National Research Council Canada

Optimizing Viral Vector Manufacturing

Michael Greene, MD, Executive Director, Technology Transfer Lead, Mustang Bio, Inc.

Directed Development of Upstream Production Processes for AAV Vectors for Reduced Cost of Goods and Improved Manufacturing Fit

Terrence Dobrowsky, PhD, Principal Engineer, Gene Therapy, Biogen


* 活動內容有可能不事先告知作更動及調整。